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Abstract
Wound healing is a complex process that consists of hemostasis and inflammation,
angiogenesis,  re-epithelialization,  and tissue remodeling.  Matrix metalloproteinases
(MMPs)  play  important  roles  in  wound healing,  and their  dysregulation  leads  to
prolonged inflammation and delayed wound healing. There are 24 MMPs in humans,
and each MMP exists in three forms, of which only the active MMPs play a role in the
pathology or repair of wounds. The current methodology does not distinguish between
the three forms of MMPs, making it challenging to investigate the roles of MMPs in
pathology and wound repair. We used a novel MMP-inhibitor-tethered affinity resin
that binds only the active form of MMPs, from which we identified and quantified active
MMP-8 and active MMP-9 in a murine diabetic model with delayed wound healing. We
showed that up-regulation of active MMP-9 plays a detrimental role whereas active
MMP-8 is involved in repairing the wound in diabetic mice. These studies identified
MMP-9 as a novel target for therapeutic intervention in the treatment of chronic wounds.
A selective inhibitor of MMP-9 that leaves MMP-8 unaffected would provide the most
effective therapy and represents a promising strategy for therapeutic intervention in the
treatment of diabetic foot ulcers.
Keywords: MMPs, chronic wounds, wound healing, selective MMP-9 inhibitor, MMP
profiling
1. Introduction
Skin is one of the largest organs in humans. Its three main functions are protection against
environmental damage, regulation of body temperature, and perception of environmental
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change. The skin consists of two distinct layers of tissue, the epidermis and dermis. The
epidermis is the outermost layer. The inner layer, dermis, provides cushioning and tensile
strength for the skin through the support of the extracellular matrix (ECM) [1]. The ECM—a
three-dimensional structure, where cutaneous cells and tissues are embedded—comprises
approximately 300 proteins, including collagen, proteoglycans, and glycoproteins [2]. Injury
to the skin would account for breaks in these protective layers, which become a cutaneous
wound. The wound has to be repaired because of its critical role in prevention of infection,
and the well-being of the tissue and the organism. Wounds that undergo a well-coordinated
cascade of biochemical events in healing are called acute wounds. On the other hand, wounds
that are recalcitrant to healing due to prolonged residency in one of the healing stages are
called chronic wounds. For wound healing to progress, the ECM has to be remodeled properly,
and endopeptidases such as matrix metalloproteinases (MMPs) contribute to this remodeling
process. Whereas these subjects have been reviewed in excellent recent articles [3–6], the
emphasis in this chapter focuses on the roles of the family of MMPs that are involved in the
wound-healing process.
Figure 1. The phases of wound healing. After tissue injury, hemostasis and inflammation start immediately, in which
cytokines, growth factors, and ROS are produced to recruit cells to the wound site. The next proliferative phases of
wound healing include angiogenesis and re-epithelialization, where new tissue is formed by endothelial cells, fibro-
blasts, and keratinocytes. In diabetic wound healing, inflammation can be prolonged, causing the wounds to be chron-
ic. The final phase is tissue remodeling. EGF (epidermal growth factor), IL (interleukin), KGF (keratinocyte growth
factor), MMPs (matrix metalloproteinases), PDGF (platelet-derived growth factor), ROS (reactive oxygen species),
TGF-β (transforming growth factor-beta), TNF (tumour necrosis factor), VEGF (vascular endothelial growth factor).
Adapted from Schreml [22].
There are currently at least 24 known MMPs in humans [7]. Not all functions that these
enzymes play in humans have been elucidated and concepts in their mechanistic roles in
wound healing are emerging only recently. Yet, it is generally appreciated that MMPs play
roles in each stage of wound healing, in large measure because of the need for restructuring
of the ECM in the process of wound healing. The phases of wound healing consist of (1)
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hemostasis and inflammation, (2) granulation and angiogenesis, (3) re-epithelialization, and
(4) tissue remodeling and are depicted in Figure 1. All four phases of wound healing have to
be coordinated and integrated properly in a timely and sequential manner for successful
healing. The repair processes require the coordination of events involving various cells, the
ECM components, growth factors, cytokines, and enzymes. Furthermore, it is increasingly
evident that MMPs display a duality of functions in the physiology of the tissue and processes
of pathology, as evidenced for chronic wounds, cancers, Parkinson’s and Alzheimer’s diseases
[8–10]. As such, certain MMPs might have a beneficial effect in healing, yet others might exhibit
detrimental effect as aberrations in the functions of these enzymes in disease development and
progression. The differentiation of these functions—detrimental versus beneficial—has been
a challenge. Yet, new tools and capabilities are becoming available to address exactly these
issues in various diseases.
1.1. Stages of wound healing
Once injury to the skin takes place, the cutaneous wound immediately enters the first phase
of hemostasis (Figure 1). The onset of blood vessel constriction prevents excessive bleeding,
which is followed by the aggregation of platelets along the damaged endothelium to form a
plug. A cascade of events ensues, which leads to the formation of a blood clot. The serine-
proteinase thrombin cleaves fibrinogen into insoluble fibrin threads that are aggregated with
platelets to create the clot. In addition to stopping the bleeding, the blood clot serves as a
provisional matrix for cell migration [11]. The surrounding cells of a blood clot also release
inflammatory cytokines and growth factors as signaling molecules to attract a variety of cells
Figure 2. ECM–growth factor interactions and production of MMPs in wound healing. Monocytes migrate to the
wound site and bind to fibronectin released by neutrophils. This interaction causes monocytes to differentiate into
macrophages that secrete multiple growth factors. TGF-β1 binds to its receptor on fibroblasts and stimulates the cells
to produce ECM components such as collagen, fibronectin, and hyaluronic acid. Neutrophils also produce MMP-8 and
-9 in the wound. Binding of AngII to macrophages stimulates the cells to produce ROS and MMPs. MMPs can cleave
laminin to release a fragment that binds EGF receptor on fibroblasts and stimulates migration and proliferation of ker-
atinocytes. AngII (angiotensin II), ECM (extracellular matrix), DDR (discoidin domain receptor), EGF (epidermal
growth factor), FGF (fibroblast growth factor), MMPs (matrix metalloproteinases), PDGF (platelet-derived growth fac-
tor), ROS (reactive oxygen species), TGF-β1 (transforming growth factor-beta 1), VEGF (vascular endothelial growth
factor).
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to the wound site to initiate the inflammatory phase. These cells include neutrophils, macro-
phages, and lymphocytes, which defend the site from infectious agents [12]. The earliest arrival
of neutrophils takes place only a few hours after injury [13]. Neutrophils are responsible for
releasing fibronectin, which has multifunctional roles, including a structural function due to
its fibrillary composition, mediating interactions between ECM components and other cells,
or serving as a bridge between cells [14, 15]. Fibronectin and fibrin act to provide provisional
matrix that promotes cellular migration and adhesion, depending on the wound status. Also,
during inflammation, fibronectin and other ECM protein fragments can attract monocytes, a
type of white blood cells, to the wound site from the bloodstream. The interactions at the
wound site cause monocytes to undergo differentiation into additional macrophages
(Figure 2) [14]. Macrophages are stimulated by growth factors to produce reactive-oxygen
species (ROS), MMPs, and multiple growth factors such as platelet-derived growth factor
(PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF),
and fibroblast growth factor (FGF) (Figure 2) [16]. One factor that can stimulate macrophages
is angiotensin II (AngII). The renin–angiotensin system (RAS) is a pathway to regulate
angiotensin, a hormone peptide, to eventually produce the primary effector-AngII [17]. This
effector is present in macrophages, neutrophils, fibroblasts, and endothelial cells of human
skin [18]. With binding and stimulation of AngII, inflammatory cells such as macrophages
generate ROS and MMPs that subsequently promote migration and proliferation of keratino-
cytes. This will be discussed in a later section of this chapter.
Among many growth factors and cytokines, TGF-βs play critical roles in regulating the
development of the ECM. There are three isoforms (TGF-β1–3) in humans, with each playing
distinct roles in regulating synthesis of the ECM components, and even cellular proliferation
or cellular death [19, 20]. TGF-βs are produced in latent forms that need to be activated by
cleavage of their pro-peptides, before exerting their activities on the ECM, which include
stimulation of cellular production of ECM components [20]. The most well known is TGF-β1,
which can control production and degradation of many constituents involved in wound
healing [14]. Once TGF-β1 binds to its receptor, this interaction stimulates the synthesis of ECM
components such as collagen, fibronectin, and hyaluronic acid in many types of cells, including
fibroblasts [21]. Fibroblasts are cells that synthesize collagen and other constituents deposited
on the ECM [14]. Besides monocytes/macrophages, fibroblasts also generate ROS, including
peroxide anion, hydroxyl ion, and superoxide anion, which are important in defense against
pathogenic microorganisms [22]. ROS, in turn, has the effect of stimulating the production of
more cytokines that lead to increased production of proteinases such as MMPs to modify
components of the ECM [22]. Dualities of functions reveal themselves in ROS as well. The
function against the pathogens is beneficial, but high-level ROS can cause damage to the ECM
components [22]. This fine balance for ROS could stimulate complex signal pathways that
would lead to up-regulation of MMPs in the wounds. The enhanced presence of ROS and the
attendant stimulated turnover of ECM components could cause tissue destruction and hinder
the repair processes [23]. This duality of roles for ROS was observed in a murine wound model
that documented severe damage to the endothelium in a background that lacked ROS-
detoxifying enzymes [24]. In diabetic patients with chronic wounds, the production of ROS
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has been found to exceed the antioxidant capacity, adding more oxidative stress to the wounds
that subsequently increases MMP levels by 60-fold over those in acute wounds [12].
Granulation and angiogenesis take place in the next phase of wound repair, which is also
known as the proliferative phase (Figure 1). Granulation tissue is defined as a matrix of
collagen, with microscopic blood vessels that are newly formed from preexisting blood vessels
in a process called angiogenesis. New blood capillaries supply oxygen to the wound tissue,
which is critical for the healing process. Granulation, in the form of a red or pink soft tissue,
forms on the surface of the wound. Macrophages are tasked with initiating this phase by
degrading the blood clots and by producing a variety of cytokines and chemokines to attract
fibroblasts to enter the wound site [22]. The population of fibroblasts at the wound site will
expand by both migration and proliferation through dynamic interaction with growth factors
and the ECM. This is mediated by integrins, a set of receptors for fibroblast, which consist of
an extracellular domain that binds to the ECM, and an intracellular portion that associates with
the cytoskeleton for biochemical signaling [25]. Integrins and discoidin domain receptor 2
(DDR2), another receptor for fibroblasts, bind to type I collagen within the ECM. This inter-
action stimulates the production of MMP-2 to promote migration of fibroblasts to the wound
site through the basement membrane during ECM remodeling [26], as indicated in Figure 2.
In addition, as mentioned earlier, TGF-β1 can stimulate proliferation of fibroblasts. The wound
tissue is hypoxic and would require a supply of oxygen for the demands of the biochemical
processes of wound healing [22]. Hypoxia stimulates macrophages, keratinocytes, fibroblasts,
and endothelial cells to produce more VEGF, which is a cytokine associated with angiogenesis
[22]. The enhanced expression of VEGF causes endothelial cells at the wound bed to migrate,
proliferate, and form new blood vessels into the wounds to supply oxygen during angiogen-
esis [27]. In addition, VEGF has been shown to increase expression of the collagen-binding
integrin in the dermal microvasculature [28]. These bindings with integrin help cells adhere
to the ECM and promote additional growth factor expression. Rossiter et al. have reported that
deletion of keratinocyte-specific VEGF impaired angiogenesis and delayed wound healing in
a murine model [29]. Other researchers have shown that overexpression of VEGF can lead to
enhanced wound healing in murine excisional wounds [30]. Another receptor that plays an
important role in cellular migration during angiogenesis is epidermal growth factor (EGF)
receptors, which can bind to EGF and laminin to enhance fibroblast migration [31, 32]. Laminin,
which is a fibrous constituent of the basement membrane, plays important roles in cell
adhesion, migration, and proliferation [33]. At the wound site, cleavage of laminin-332 (also
referred to as laminin-5) by MMPs would generate a fragmented laminin peptide that binds
to the EGF receptor and enhances the cellular motility of proliferating keratinocytes [34],
demonstrated in Figure 2. In addition to its role in angiogenesis, fibroblasts are responsible for
the production and deposition of immature collagen (type III collagen), which is essential in
providing more strength for the wound ECM [22].
The formation of granulation tissue in the last phase provides a support matrix for epithe-
lial cells to migrate across and to cover the wound surface in a process known as re-epi-
thelialization (Figure 1). This stage of wound healing mainly involves keratinocytes,
which are a predominant cell type in the epidermis of the skin [35]. In fact, to cover the
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wound surface with a new layer of epithelium, the keratinocytes at the wound edge need
to undergo migration, differentiation, and proliferation. In the basal layer of epidermis,
keratinocytes have differentiating characteristics, in which they are able to change into a
longer and flatter shape before they begin migration [35]. The migrating keratinocytes
need to loosen their adhesion to each other before moving away from the wound edge
toward the wound’s central point to close the open area [35]. It is interesting to note that
these cells need to establish adhesion to the new ECM around them via integrins, but at
the same time they develop actin filaments to support cellular migration through a
wound matrix of necrotic material, clots, and even bacteria [36, 37]. During this process,
the continued enhanced expression of MMPs, released by a variety of cells (macrophages,
keratinocytes, endothelial cells, and fibroblasts) plays crucial roles in degrading substrates
of the provisional wound matrix [38]. After the first layer of cells that cover the wound
area, keratinocytes need to proliferate to have adequate depth of cells in the wound. The
onset of proliferation is brought about by a variety of factors such as EGF, TGF-α, TGF-β,
keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF) [39]. The migra-
tion and proliferation of these cells require increased supply of oxygen in the wound bed
[22]. It is important to note that in chronic wounds, the epidermis fails to re-epithelialize
due to non-migratory keratinocytes, compared to acute wounds [35]. Following the robust
proliferation and epithelial migration, wound healing enters its last phase of tissue re-
modeling that could potentially last in the order of years. Type III collagen prevalent dur-
ing this last phase is gradually replaced by the more stable type I collagen [22]. The
collagen fibers at the wound site are rearranged, cross-linked, and aligned to increase the
wound’s tensile strength [40]. The participation of proteinases is necessary to ensure ECM
remodeling, which will bring back normality to the tissue.
In the repair of acute wounds, interactions between growth factors and the ECM occur in
an orchestrated manner, where each phase is allowed to transition properly to the next,
resulting in a healed wound. There are numerous factors that contribute to the impair-
ment of wound healing in patients. Some are local factors that directly affect wound clo-
sure such as supply of oxygen, infection, venous sufficiency, and imbalance between
proteinases or growth factors [12]. Others are underlying conditions that influence the
overall health of a patient, including age, diseases, obesity, medications, and an immuno-
compromised system [12]. For instance, septic conditions have been shown to delay
wound healing in mice [41]. In the case of patients affected by hypoproteinemia, their
protein deficiency can impair wound healing by affecting capillary formation, cellular pro-
liferation, collagen deposition, and wound remodeling [12]. The most detrimental disease
is diabetes, where patients are more prone to develop non-healing ulcers or chronic
wounds. In these wounds, the interactions between growth factors and the ECM are dis-
rupted because of biochemical abnormalities of the ECM and aberrantly elevated activities
of MMPs [14]. The imbalance between MMPs and their endogenous regulators can cause
excessive degradative activities and critical loss of the newly reformed ECM in wound
healing.
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1.2. Matrix metalloproteinases (MMPs): structures and regulation
Matrix metalloproteinases are a group of 24 enzymes in humans—there are a total of 28 MMPs
known to date, including enzymes from other organisms—which are expressed as zymogenic
inactive proteins [7]. These enzymes are highly regulated and one level of regulation is exerted
in their proteolytic activation by other proteinases, including by other MMPs [42, 43]. As the
pro-domain of the zymogens are removed, the active sites become available for catalysis.
Tissue inhibitors of matrix metalloproteinases (TIMPs) are protein inhibitors of these enzymes
that form non-covalent complexes with the catalytic domain. The activation events and the
inhibition by TIMPs account for various steps in the regulation process, which we will expand
on in the following sections. These events are graphically depicted in Figure 3 for MMP-2.
Figure 3. MMPs, as exemplified in this figure by MMP-2, exist in three forms: pro-MMPs (inactive), active MMPs, and
TIMP-complexed MMPs (inactive). MMPs are first produced as latent pro-MMPs (1) with a pro-domain (shown in red)
blocking the active site (shown in yellow). The removal of the pro-domain is required to activate MMPs by revealing
the zinc ion in the catalytic site (2). Active MMPs are then able to cleave substrates. The activity of MMPs is regulated
by interaction with TIMPs (shown in purple), which inactivate the MMPs (3).
MMPs are zinc-dependent endopeptidases. They are either secreted into the ECM or are
membrane-anchored on the surface of the cell [9, 44, 45]. The most basic components of all
MMPs consist of three domains: a signal sequence at the N-terminus, a pro-domain that caps
the active site, and a catalytic domain, as depicted in Figure 4. This minimal domain organi-
zation is present in MMP-7 and MMP-26, also known as the matrilysins. The catalytic domain
is characterized by the zinc-binding HExxHxxGxxH motif, containing three conserved
histidines [46]. Several MMPs have an additional domain referred to as the hemopexin-like
domain, which is linked at the C-terminus of the aforementioned basic sequence. The hemo-
pexin-like domain is believed to play a role in substrate recognition. This organization of
domains for MMPs is seen in MMP-3 and -10 (also known as stromelysin-1 and-2), MMP-1, -8,
and -13 (also known as collagenases), MMP-12 (metalloelastase), MMP-20 (enamelysin), and
MMP-22 and -27 [47] (Figure 4). MMP-2 and MMP-9 (or gelatinases) have more complicated
structures by having fibronectin repeats inserted into the side of the catalytic sites [47]
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(Figure 4). The membrane-bound MMPs have two types of membrane anchors. One is a
transmembrane peptide domain and another is the GPI anchor (Figure 4). There are a few
other variations, which are summarized in Figure 4 graphically. The structural similarities
among these MMPs are high. Certainly, individual domains are highly similar in both sequence
and three-dimensional structures. As a consequence, these enzymes share significant overlap
in their substrate preferences, which is likely a reflection of the fact that the functions of
disparate MMPs in the physiology of the organism are critical and they exhibit some redun-
dancy in their turnover of the substrates as a consequence. As it pertains to wound healing,
important MMPs and their known substrates are listed in Table 1.
Figure 4. Structures of the MMP family. MMPs are divided into eight subgroups based on structural similarities. Pre:
signal sequence, Pro: pro-peptide, Zn2+: zinc-binding site, Catalytic: catalytic domain, F: repeats of fibronectin, Fu: fur-
in-like serine proteinases, Vn: vitronectin-like insert, TM: transmembrane domain, GPI: glycosylphosphatidylinositol,
SA: N-terminal signal anchor, CA: cysteine array, Ig-Like: immunoglobulin-like.
As indicated earlier, the functions of these enzymes are highly regulated. This regulation
manifests itself at the transcriptional level as well as at the proteome level. Production of MMPs
is stimulated in a variety of cells such as keratinocytes, fibroblasts, endothelial cells, and
inflammatory cells during wound healing. These cells can be transcriptionally activated by a
wide range of cytokines and growth factors including EGF, HGF, FGF, TGF-β, VEGF, PDGF,
and KGF, as well as by interleukins and interferons [74]. Since there are many cytokines with
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the ability to activate transcription to produce the zymogens, there are numerous signaling
pathways implicated in the control of proteinase expression. These pathways include, for
instance, mitogen-activated protein kinase (MAPK), or growth factor-dependent pathways of
Smad, NF-kB, activation of focal adhesion kinase (FAK) by integrin activation, or Wnt cascade
[11]. The highly regulated process is critical for the physiological roles. When the regulation
goes awry, these enzymes cause pathological consequences. The pathological outcomes of
MMP dysregulation have been the subject of many review articles [8, 10, 75, 76].
MMP Preferred
Substrates 
Roles in Wound Healing Cell
culture
Human
(H) or
Mouse
(M)
wounds
Detection Method
MMP-1
(collagenase-1)
Collagen I, II, III,
VII and X;
aggrecan, serpins;
alpha2-
macroglobulin
• Promotes human
keratinocyte migration on
fibrillar collagen [38]
X 35S-labeled antisense RNA
probes [38]
• Overexpression in
keratinocytes delays re-
epithelialization [38]
X
• Expressed by keratinocytes at
their trailing membrane edge
during wound healing [48]
X H Competitive ELISA [48]
• Found to be elevated in diabetic
foot ulcer patients [49]
H
MMP-2
(gelatinase A)
Gelatin; collagen I,
IV, V, VII, and X;
laminin; aggrecan;
fibronectin; tenascin
• Expressed by fibroblasts and
endothelial cells in both mouse
[50] and human acute wounds
[51]
M
H
ELISA and gelatin
zymography [51]
• Accelerates cell migration
[34]
X
• Expressed in platelets,
mediates platelet adhesion and
aggregation [52]
X
• Keratinocyte migration [34] X
• Activates MMP-9 [53] X
MMP-3
(stromelysin-1)
Collagen IV, V, IX,
and X; fibronectin;
elastin; gelatin;
• Expressed by basal
keratinocytes in both human
acute and chronic wounds [54]
H 35S-labeled antisense RNA
probes [54, 57]
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MMP Preferred
Substrates 
Roles in Wound Healing Cell
culture
Human
(H) or
Mouse
(M)
wounds
Detection Method
aggrecan; nidogen;
fibrillin; E-cadherin
• Affects wound contraction
and delayed healing [55]
M
• Activates MMP-9 [56] X
MMP-7
(matrilysin)
Elastin; fibronectin;
laminin; nidogen;
collagen IV;
tenascin: versican;
α1-proteinase
inhibitor; E-cadherin;
tumour necrosis
factor
• Required for re-
epithelialization of
mucosal wounds [58]
M Immunohistochemistry
[59]
• Re-epithelialization of mucosal
tissue is impaired in MMP-7
knockout mice [58]
M
MMP-8
(collagenase-2)
Collagen I, II,
and III; aggrecan,
serpins; 2-MG
• Mainly expressed by
neutrophils [3]
Western blot [62]
• Promotes cutaneous diabetic
wound healing [60]
M MMP-inhibitor-tethered
affinity resin [60]
• Most prevalent collagenase in
wounds [61]
H
• MMP-8 knockout mice show
delayed wound closure [62]
M
• Found to be elevated in
diabetic foot ulcer patients [49]
H
• Selective inhibition of MMP-8
delays murine diabetic wound
healing [60]
M In-situ zymography [63]
• Topical application of active
MMP-8 accelerates murine
diabetic wound healing [63]
M
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MMP Preferred
Substrates 
Roles in Wound Healing Cell
culture
Human
(H) or
Mouse
(M)
wounds
Detection Method
MMP-9
(gelatinase B)
Gelatin; collagen
I,III,IV, V and VII;
aggrecan; elastin;
fibrillin
• Hypoxia induces cell migration
through increased expression of
MMP-9 [64]
M Immunohistochemistry
and gelatin zymography
[51]
• Upregulation causes
detrimental effects in murine
diabetic wounds [60]
M • MMP-inhibitor-tethered
affinity resin [60]
• Keratinocyte migration [65]   X
• Increased levels in wound fluid
of diabetic foot ulcers, quantified
by gelatin zymography [49]
H
• MMP-9 knockout diabetic mice
have reduced re-epithelialization
and delayed wound closure [63]
M
• Selective inhibition of MMP-9
accelerates diabetic wound
healing [60, 63]
M In-situ zymography [63]
MMP-10
(stromelysin-2)
Collagen IV, V, IX,
and X; fibronectin;
elastin; gelatin;
laminin; aggrecan;
nidogen; E-cadherin
• Expressed by epidermal cells
three days post-wounding in
human wounds [66]
H 35S-labeled antisense RNA
probes [57, 66]
• Overexpression in
keratinocytes resulted in normal
wound healing but disorganized
epithelium [67]
M • RNA probes [67]
MMP-12
(metalloelastase)
Collagen IV;
gelatin; fibronectin;
laminin; vitronectin;
elastin; fibrillin;
apolipoprotein A;
α1-proteinase
inhibitor
• Expressed specifically in
macrophages, but not expressed
by epithelial cells [50]
M RNA isolation and RNase
protection analysis [50]
• Potential regulator of
angiogenesis due to ability to
generate angiostatin [68]
X Western blot [68]
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MMP Preferred
Substrates 
Roles in Wound Healing Cell
culture
Human
(H) or
Mouse
(M)
wounds
Detection Method
MMP-13
(collagnase-3)
Collagen I, II, III,
IV, IX, X and XIV;
gelatin; fibronectin;
laminin; tenascin;
aggrecan; fibrillin;
serpins
• Promotes re-epithelialization
indirectly by affecting wound
contraction [69]
X mRNA and
immunohistochemistry [70]
• Keratinocyte migration [70] M
• MMP-13 knockout mice have
reduced re-epithelialization and
delayed wound closure [70]
M
MMP-14 (MT1-
MMP)
Collagen I,II,
and III; gelatin;
fibronectin; laminin;
vitronectin;
aggrecan; tenascin;
nidogen; perlecan;
fibrillin; α1-
proteinase inhibitor,
α2-macroglobulin
• Promotes keratinocyte
migration and invasion [71]
35S-labeled antisense RNA
probes [72]
• Involved in KGFR expression,
and can regulate epithelial cell
proliferation [72]
M
• Activates MMP-2 [73] X
Adapted from Martins and Caley [3].
Table 1. Mammalian MMPs: enzymatic substrates and roles in wound healing.
The complex orchestration of events that we outlined in Section 1.1 on wound healing involves
important roles by MMPs. However, since MMPs are highly regulated at the proteome level,
the transcriptional regulation is not the full picture. Yet, the transcriptional regulation of MMPs
is the most studied, as the tools for it are readily available. For example, the increased tran-
scription leads to higher translation to the inactive MMP zymogens, which have to experience
proteolytic activation. This activation may only require disruption of the interaction between
the active-site zinc ion and the conserved cysteine residue from the sequence …PRCGVPD…
of the pro-domain to give rise to the active MMPs [3]. During physiological processes, pro-
MMP activation can be achieved either by serine proteinases or by other MMPs [6]. In
Wound Healing - New insights into Ancient Challenges48
particular, membrane-type MMPs have been shown to be capable of activating other pro-
MMPs, both directly and indirectly. For instance, MMP-14 (or MT1-MMP) is involved in
regulating activation of pro-MMP-9 in osteoclast migration [77]. Activation of MMPs by serine
proteinases is regulated by inhibition of plasma proteinase inhibitors, including α1-proteinase
and α2-macroglobulin or thrombospondin-1 and thrombospondin-2 [3]. The activity of MMPs
is primarily regulated in vivo by endogenous tissue inhibitors of metalloproteinases (TIMPs)
(Figure 3). In mammals, there are four TIMPs (TIMP-1, -2, -3, and -4) that bind specifically to
inhibit MMPs [78]. The dysregulation such as imbalance between MMPs and TIMPs ratio leads
to up-regulation of proteinase activity and damage to the ECM.
Method Advantages Limitations
mRNA and RT-PCR Quick, simple, and
inexpensive
Does not measure amount and activity of the
proteinases
Western blot and
immunohistochemistry
Simple, sensitive, and
specific
Requires specific and expensive antibodies and does
not distinguish between zymogen, active, and TIMP-
complexed MMPs
Gelatin zymography Inexpensive materials,
semi-quantitative
Unable to distinguish between active and TIMP-
complexed MMPs, low sensitivity
In-situ zymography Identification of MMPs
can be done in tissues
Limited to availability of fluorescent substrates, but
not quantitative, and hard to discriminate between
different MMPs, low sensitivity
Activity-based enzyme profiling Specificity Requires library of selective MMP-directed probes
TAPI-2 affinity resin Identifies active MMPs Starting materials are very expensive and requires
user linking of TAPI to the resin
MMP inhibitor–tethered affinity
resin
Identifies and quantifies
active MMPs
Requires synthesis of MMP-inhibitor covalently
attached to the resin
Adapted from Fisher and Mobashery [76].
Table 2. Profiling methods for MMPs.
Once activated, the only MMP form that is not complexed by TIMPs would have catalytic
competence. Hence, tools are needed for analysis at the protein level in the afflicted/diseased
tissue. Many current methodologies to profile MMPs are limited because they are unable to
detect active MMPs (summarized in Table 2). We have applied unique tools to this end in both
diabetic and non-diabetic wounds. An MMP-inhibitor-tethered affinity resin that binds
exclusively to the active forms of MMPs was used to fish out activated MMPs that exist in
wound tissues [60]. Once bound, the active MMPs were digested with trypsin and the peptides
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were analyzed by liquid chromatography—mass spectrometry/mass spectrometry (LC-MS/
MS); the proteinases were identified from the peptides MS/MS data and a protein database
search [60] (Figure 5). Subsequently, each identified active MMP was quantified using LC-MS/
MS methods and custom-synthesized peptides. This analysis led to the discovery of active
MMP-8 and MMP-9 in both diabetic and non-diabetic wounds from mice. The quantification
revealed that MMP-9 was elevated at statistically significant levels, whereas levels of MMP-8
were slightly up-regulated after seven days from infliction of the wound [60].
Figure 5. MMP-inhibitor-tethered affinity resin to identify and quantify active MMPs. Wound tissues are homogen-
ized, and the homogenate is incubated with the MMP-inhibitor-tethered affinity resin, which binds only to active
MMPs. The isolated active MMPs are reduced (to reduce disulfide bonds between the thiol groups of cysteine in
MMPs), alkylated (to prevent reformation of disulfide bonds), and trypsin digested. The resulting peptides are ana-
lyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and identified by a protein database. The
identified MMPs are quantified using three peptides and three transitions per peptide using LC with multiple-reaction
monitoring (MRM). In this highly specific quantitative MS method, the ionized peptide selected in the first quadrupole
(Q1) generates to a pool of fragments in the second quadrupole (Q2), where the highest intensity fragment ion is select-
ed for monitoring in the third quadrupole (Q3). This transition from peptide to fragment ion is monitored, and the area
under this peak is integrated. Finally, the concentrations of active MMPs in wound samples are quantified by using
peak area ratios relative to the internal standard and calibration curve regression parameters.
Whereas these studies were followed up by investigations of knockout mice as well, the
knockout mice do not provide a superior opportunity for elucidation of the functions of MMPs
in our opinion. Knockout MMP-9 mice, which survive the embryonic stage, were made diabetic
to explore the role of the enzyme. We hasten to add that the compensatory activities of other
MMPs in light of the overlapping profiles for the substrates create ambiguity in interpretation
of the data. These compensatory activities will be present throughout the embryonic devel-
opment up to the point in which the experiment is conducted with these mice. The more
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superior approach, in our opinion, in elucidating the roles of the two enzymes (MMP-8 and
MMP-9) is the use of selective pharmacological agents that afford total temporal control of
abrogation of activity within the wounds in the time course of the experiments. Highly selective
or specific inhibitors for the given enzyme are critical for the success of these studies. These
investigations indeed revealed the duality of MMP functions, beneficial and detrimental, in
diabetic wounds [60, 63]. It was documented that MMP-8 had a beneficial role in wound
healing, as it might be the body’s response to the healing process. On the other hand, MMP-9
was shown to serve a detrimental role in diabetic wound healing; hence, an aberration in the
regulatory events in diabetic animals led to its formation with detrimental consequences.
Indeed, pharmacological intervention by selective MMP-9 inhibitors with no activity toward
MMP-8 would appear to be a promising approach to speed up healing of diabetic wounds. As
the non-healing wounds remain open for a long period of time, they face the fatal threat of
infections with methicillin-resistant Staphylococcus aureus [79, 80] that lead to amputations like
in the case of diabetic foot infections [81]. There is a serious need to develop new approaches
to facilitate healing in chronic wounds since current treatments have not been proven effective.
The only FDA approved drug Regranex™ (becaplermin), a platelet-derived growth factor, is
associated with malignancies and increased risk of death [82]. In addition, the effectiveness of
negative-pressure wound therapy is still unclear, stem cell therapies do not clear the infection,
or topical antibiotics, and antimicrobial dressings induce antibiotic resistance [81].
2. Detection of matrix metalloproteinases in tissue
As indicated above, MMPs are usually not detectable in normal adult tissues, but are up-
regulated in disease. The tools available for assessment of MMP levels are quantification of
mRNA, reverse transcription-polymerase chain reaction (RT-PCR), Western blotting and
immunohistochemistry, gelatin zymography, in-situ gelatin zymography, activity-based
enzyme profiling, and TAPI-2 resin [76]. However, these tools generally do not reveal whether
the elevated levels of the MMPs that are being monitored are due to the inactive zymogenic
forms, the active MMPs, or the MMPs in complex with TIMPs (inactive forms). Quantification
of mRNA levels by Northern blot analysis and RT-PCR are limited in that these methods
measure mRNA levels and not the amount and activity of the protein. Immunohistochemistry
and Western blot require specific antibodies, which usually cannot distinguish between active
and TIMP-inhibited MMPs, and might exhibit cross-reactivity. The sensitivity of zymography
is not typically high, and this method also detects TIMP-complexed MMPs. in-situ zymography
is limited by the availability of fluorescent proteinase substrates, which at present can be
performed for MMP-1, -2, -3, -7, -8, -9, -12, -13, and -25. This method has limitations for
quantitative determinations. Activity-based enzyme profiling of MMPs requires a library of
selective MMP-directed probes [76]. A TAPI-2 affinity resin has been reported to identify active
MMPs [76]. However, it is very expensive. With the exception of the TAPI-2 resin, the other
methods do not identify and quantify the active forms of MMPs. A summary of advantages
and limitations of these methods is given in Table 2. We add that another complication in these
studies is that the active MMPs formed in diseased tissue might be present in minute quantities,
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such that conventional detection methods at the proteome level might not be able to identify
them. We reiterate that of the MMP forms, only the active MMPs in the absence of TIMP
complexation would be able to perform its function in manifestation of the disease.
Expression of MMPs in normal uninjured skin is generally low. However, their activities are
thought to be up-regulated when cutaneous wounds occur. For instance, low RNA expression
levels of MMP-2 and MT1-MMP were reported in uninjured murine skin [50]. Once the
cutaneous injury happens, up-regulation and expression of many MMPs have been reported,
including collagenases (MMP-1 [83], MMP-8 [60, 61], and MMP-13 [70]), gelatinases (MMP-2
[51] and MMP-9 [51, 60]), stromelysins (MMP-3 and MMP-10 [54]), and other MMPs such as
MMP-7 [58], MMP-12 [50], and MMP-14 [51]. However, it should be noted that most of these
studies employed methods that do not distinguish between the active or inactive forms of
MMPs, except the aforementioned TAPI-2 resin and the recent methodology that couples an
MMP-inhibitor-tethered affinity resin with mass spectrometry, as mentioned in the previous
section [60]. As such, observation of up-regulation or even the expression of a particular MMP
does not necessarily imply a role for that MMP in wound healing. Parallel to MMPs, the
expression of TIMPs is often increased in order to regulate the proteinase activities [84]. Hence,
the biochemical imbalance that leads to aberrant consequence has to be the focus of research
in elucidating the mechanistic basis of disease.
2.1. Beneficial roles of MMPs in wound repair
Collagenases have been implicated in wound healing for many years. As the name implies,
these proteinases prefer to turn over various types of collagen (types I, II, and III), which is an
important process in wound repair (Table 1). MMP-1, expressed by keratinocytes about a week
after injury occurs, might facilitate keratinocyte migration when these cells come into contact
with type I collagen in the early re-epithelization phase [83]. The interaction between kerati-
nocytes at the wound edge and type I collagen in the matrix via the α2β1 integrin receptor
enhances the expression of MMP-1 [38]. MMP-1 cleaves type I collagen to generate cleaved
fragments, which have been suggested to become a less adhesive binding ligand than the native
protein and that loosens the matrix environment for cellular movements. Thus, the complex
of MMP-1 and α2β1 promotes migration of keratinocyte on type I collagen in the re-epitheli-
alization phase, as shown in Figure 6. However, α2β1 integrin-deficient mice still retain normal
re-epithelialization, collagen deposition, and tensile strength, which indicate a possible
compensatory mechanism by another integrin receptor [85]. Once the new basement mem-
brane is established after re-epithelialization, the epidermal expression of MMP-1 is terminated
by cellular contacts with proteins from the membrane. Specifically, the contact between
keratinocytes with laminin-111 (previously called laminin-1) leads to the repression of MMP-1
in the presence of type I collagen [86]. Expression of MMP-1 has also been observed in
fibroblasts during granulation and angiogenesis [83], where the enzyme might act to remodel
the ECM of the wound [87]. Interestingly, overexpression of human MMP-1 in the epidermis
of transgenic mice resulted in delayed wound closure; however, the genomic modification with
human DNA in these animals may have resulted in unwanted phenotypes [88].
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Figure 6. Involvement of MMPs in the wound‐healing process. The healed or healthy skin, consisting of ECM and
blood vessels, is populated by fibroblasts. Once the skin is damaged by a full‐thickness injury, it becomes a cutaneous
wound. In the early phase of inflammation, the wound is occupied with fibrin clot to seal the wound, and levels of
MMP‐2 and MMP‐9 are increased. Fibroblasts and macrophages migrate into the wound site, where they are stimulat‐
ed to release more MMPs to remodel the ECM. The inflammation phase is followed by angiogenesis, in which the up‐
regulation of a variety of MMPs (including MMP‐1, MMP‐8, MMP‐9, and MMP‐13) would stimulate epithelial cells
(keratinocytes) to proliferate and migrate to re‐epithelialize over the wound area. However, prolonged inflammation
could cause the wounds to become chronic, as it has been observed in diabetic foot ulcers. During chronic wounds, the
irregular up‐regulation of MMP‐9 has been associated with reduction of MMP‐8 and plays a detrimental role in ECM
remodeling. Tissue remodeling and expression of MMPs are attenuated when the epithelial cells proliferate and differ‐
entiate in order to reform the new epithelium. During this last phase of wound healing, fibroblasts can continue to
remodel the underlying dermis over a period of several months.
Expression of human MMP‐1 has shown similar patterns to expression of murine MMP‐13 in
an excisional wound healing model (Figure 6) [50, 89]. Both MMP‐1 and MMP‐13 may share
roles in promoting the survival of fibroblasts while remodeling collagen deposition in the
wound ECM [69]. Hattori et al. have shown that MMP‐13 knockout mice had both delayed re‐
epithelialization and wound closure (Table 3) [70]. However, in another study, MMP‐13
knockout mice showed normal efficiency of re‐epithelialization, wound closure, inflammatory
response, and unaltered remodeling of the wound matrix [90]. The inconclusive evidence on
the role of MMP‐13 in wound repair could in principle be explained by the redundancy in
functions of proteinases that we mentioned earlier. There was up‐regulated expression of
MMP‐8 (or collagenase‐2) in these MMP‐13‐deficient animals [90], for example. The relevance
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of MMP-8 in wound repair was unclear until this study indicated that there is enzymatic
compensation by MMP-8 to facilitate normal wound healing [90]. There is mounting evidence
that MMP-8 plays a beneficial role in repairing the wounds. As MMP-8 is expressed and
secreted mostly by neutrophils, its expression peaks after four days in non-diabetic wounds,
detected by ELISA [61]. In humans, MMP-8 is the most prevalent collagenase in cutaneous
wounds, where it is required for debridement of the wound and for the removal of damaged
type I collagen [61]. Yet, it is still challenging to conclude whether this is the active form of
MMP-8 by the methods that were used. In mice, the exact levels of active MMP-8 were
quantitatively determined by the use of an MMP-inhibitor-tethered affinity resin coupled with
mass spectrometry [60]. In this study, Gooyit et al. also demonstrated that selective inhibition
of MMP-8 caused delayed wound healing and incomplete re-epithelialization in diabetic mice
[60]. In addition, MMP-8-deficient mice displayed a significant delay in wound healing, caused
by a lag in neutrophil infiltration, persistent inflammation and impaired re-epithelialization
(Table 3) [62]. However, MMP-8 knockout mice show compensation in MMP-9 [62], making
it difficult to separate the roles of MMP-8 and MMP-9 in wound healing. Furthermore, topical
application of active recombinant MMP-8 on murine diabetic wounds resulted in a significant
acceleration in both wound healing and re-epithelialization [63]. These studies reveal the
beneficial role of MMP-8 in wound healing, where the neutrophil-derived MMP-8 can facilitate
repair processes by providing debridement for damaged proteins and paving a pathway for
the formation of the provisional matrix for keratinocyte migration (Figure 6).
Gene Modification Wound phenotype Reference
hmmp-1 Overexpression in
keratinocytes
Delayed re-epithelialization [88]
mmp-3 Knockout Impaired wound contraction [55]
mmp-8 Knockout Delayed re-epithelialization, delayed arrival of and prolonged
inflammation
[62]
mmp-9 Knockout Enhanced re-epithelization, accelerated wound closure [63, 64]
mmp-10 Overexpression in KCs Unaltered wound closure, scattered epithelialization [67]
mmp-13 Knockout Delayed wound closure, and reduced re-epithelialization [70]
mmp-14 Knockout Unaltered wound closure over 7 days’ but premature morbidity and
mortality were observed in these mice
[92, 93]
Table 3. Metalloproteinase gene targeting in mice studies and wound phenotypes.
The underlying cause of diabetic complications leads to up-regulation of MMP-9 compared to
MMP-8. For instance, biopsy samples from diabetic patients revealed only two-fold increase
in MMP-8, but 14-fold increase in MMP-9 expression when compared to non-diabetic tissues
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[49]. Although the application of recombinant MMP-8 accelerated healing of full-thickness
wounds in diabetic mice, it might have a similar beneficial mechanism as the marketed drug
Santyl®, which is indicated for debridement of chronic dermal ulcers and severely burned areas
and contains collagenase derived from Clostridium histolyticum. Clinical evidence suggests that
collagenase treatment expedites the removal of necrotic tissues and enhances keratinocyte
migration [91]. When used after debridement, Santyl® promotes wound healing in patients
with pressure ulcers, venous leg ulcers, diabetic ulcers, and severely burnt wounds [91].
However, excessive use of active recombinant MMP-8 may affect the formation of new ECM
and may not be beneficial in wound healing. A dose-response study with active recombinant
MMP-8 topically administered to wounds of diabetic mice showed that higher levels of this
proteinase did not accelerate wound healing [63].
Gelatinases, MMP-2 and MMP-9, are also involved in wound repair. Early expression of both
gelatinases is observed in platelets, where MMP-9 is involved in platelet production and
MMP-2 mediates platelet adhesion and aggregation [52]. The early expression of gelatinases
might contribute to degradation of gelatin matrix in biofilm produced by bacteria [94]. This
degradation serves to weaken the attachment of bacterial biofilm to the wound site and might
be a strategy in fighting infection [94]. In addition, gelatinases are able to digest various
constituents of the wound matrix to initiate angiogenesis in the repair processes. After tissue
injury, AngII, which plays roles in inflammation, cell proliferation, and migration, would
stimulate macrophages and neutrophils to generate ROS and MMPs to promote cell adhesion
and ECM formation [17]. Specifically, AngII has been shown to induce the expression of both
gelatinases, MMP-2 [95] and MMP-9 [96, 97]. AngII has been demonstrated to promote
angiogenesis via activation of VEGF and endothelial nitric oxide [98], whereas studies with
AngII-type 1a receptor knockout mice or with inhibition of AngII receptor have resulted in
delayed wound healing with reduced angiogenesis in animals [99]. Given the beneficial role
of AngII in angiogenesis of wound healing, it is interesting to note that there is discrepancy in
the outcomes of diseases treated with this factor’s inhibitors. These inhibitors can either block
AngII receptors or inhibit the enzyme that generates factor AngII in the RAS pathway. In
cancer, AngII inhibitors have been shown to reduce the tumor-related VEGF expression,
angiogenesis, and tumor size [16]. These drugs are also used to treat hypertension, in which
dysregulation of RAS causes poor blood flow, inadequate supply of oxygen, and impaired
wound healing [12]. When used in anti-hypertensive therapy, drugs such as losartan has been
demonstrated to promote wound healing in diabetes-induced mice by improving vascular
perfusion, without affecting VEGF expression [100]. To this extent, anti-hypertensive therapy
appears to be beneficial for wound healing. Thus, there is a need for further research to
elucidate the precise role of these inhibitors in diabetic patients with impaired wound healing.
Expression of MMP-2 is demonstrated to coincide with expression of laminin-332 (also referred
to as laminin-5) during enhanced keratinocyte migration in wound healing [101]. Since both
MMP-2 and MMP-9 can cleave the gamma-2 chain of laminin-322 [102], they result in a pro-
migratory and EGF-like fragment that binds EGF receptor to trigger cell migration of kerati-
nocytes at the wound matrix [34], demonstrated in Figure 2. This cleaved fragment has been
found in both tumors and tissues that undergo remodeling, except for intact epidermis [34,
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103, 104]. Interestingly, MMP-8 also cleaves laminin-332, which indicates the mechanistic
redundancy of the roles of MMPs during wound healing [102]. Furthermore, the two gelati-
nases might contribute to angiogenesis possibly by activating cytokines such as TNF-α (tumor
necrosis factor-alpha) [105] and VEGF [106, 107]. However, cleavage of laminin-332 by MMP-2
has only been shown in tumor cells and normal breast epithelial cells, but not in normal
keratinocytes in wound repair. Some studies have implicated MMP-2 in cleaving the latency-
associated peptide (LAP) of pro-TGF-β and latent TGF-β binding protein (LTBP) to release
activated TGF-β to bind the ECM [108–110]. Another study has also indicated that the active
form of MMP-2 can activate MMP-9 in cell culture [53]. Pro-MMP-2 itself needs to be activated,
and it has been shown that this activation requires the cluster of MMP-14, pro-MMP-2, and
αVβ3 integrin in a model of breast cancer cells [111]. It is important to note that active MMP-2
was not observed in wounds of diabetic and non-diabetic mice in the studies that used the
MMP-inhibitor-tethered affinity resin, described earlier [60]. Therefore, the role of MMP-2
during wound healing has remained obscured with no in vivo verification to date. In fact, the
study that implicated both active MMP-2 and MMP-9 in human wound healing used gelatin
zymography as the tool [112]. However, this method lacks the ability to detect exclusively the
active MMPs in the wound tissues, because the denaturation of the TIMP-MMP complex
during electrophoresis could also result in an active MMP-2 band (Table 2). On the other hand,
inhibition of MMP-9 activity with an antibody or MMP-9 ablation has delayed keratinocyte
migration in vitro, which indicates the necessary involvement of MMP-9 during normal wound
closure [65]. Others have also demonstrated in vitro that MMP-9 appears to promote kerati-
nocyte migration [113]. Indeed, the study with the MMP-inhibitor-tethered affinity resin
revealed that active MMP-9 was essentially undetectable in the intact skin, but it was expressed
as early as one day after injury and remained up-regulated throughout the two weeks of study
in non-diabetic and diabetic mice [60]. In the case of diabetic mice with delayed wound closure,
the analysis showed up-regulation of active MMP-9, which could be detrimental to the repair
process [60]. Besides promoting angiogenesis, gelatinases and other MMPs interestingly can
inhibit angiogenesis by generating anti-angiogenic peptides from other precursor proteins. For
instance, distinct proteinases such as MMP-3, -7, -9, -13, and -20 have been shown to generate
active endostatin from human collagen XVIII [114] in vitro, whereas MMP-2, -3, -7, -9, and -12
are responsible for generating angiostatin from plasminogen [68, 115].
Expression of MMP-3 and MMP-10 (two stromelysins) has been found in epidermal cells
during human and murine wound healing using RNA probes (Table 1). MMP-3 is expressed
by the basal-proliferating keratinocytes, which are in contact with the intact basement
membrane and close to the wound edge [54]. Expression of MMP-3 is also detected in
fibroblasts during wound healing [11]. Research has shown that wound closure was delayed
in non-diabetic MMP-3 knockout mice due to impaired wound contraction (Table 3) [55]. The
implicated involvement of MMP-3 in normal wound healing may have resulted from demon-
stration that MMP-3 could activate MMP-9 [56], the gelatinase that plays roles in keratinocyte
migration. However, MMP-2 could also trigger activation of MMP-9 [53], which corroborates
the possibility of mechanistic compensation by other MMPs in physiology. Thus, the involve-
ment of MMP-3 in the repair processes of wound healing still remains ambiguous. Nonethe-
less, it has been demonstrated that MMP-3 can activate several pro-MMPs, digest many ECM
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components, and increase the availability, as well as the activities, of cytokines and growth
factors [116]. These findings disclose roles for MMP-3 in cell migration and proliferation during
wound repair.
Meanwhile, MMP-10 (stromelysin-2), is expressed with a different pattern even though both
MMP-3 and MMP-10 can degrade several collagens and non-collagenous connective tissue
substrates, including proteoglycans, gelatin, fibronectin, and laminin [117], as indicated in
Table 1. Human MMP-10 is expressed by epidermal cells about three days post-wounding,
where its regulation seems to depend on EGF, TGF-β, and TNF-α cytokines [66]. The role of
MMP-10 in wound repair was investigated by overexpressing a constitutively active MMP-10
mutant in keratinocytes, which resulted in normal wound-healing architecture and normal
wound-healing rate in these transgenic mice [67]. However, the epidermal histology was
demonstrated to have a disorganized migrating epithelium, composed of degradation in the
newly formed matrix via laminin-332, abnormal cell-to-cell contacts of keratinocytes, and
finally an increased rate of apoptosis of keratinocytes [67]. These findings indicate that levels
of MMP-10 require a tightly regulated expression to facilitate keratinocyte migration during
wound healing. Although both stromelysins would appear to be players, more investigations
are needed to ascertain the roles of active MMP-3 and MMP-10 in the physiology of wound
repair.
In addition to gelatinases and collagenases, other MMPs might have roles in wound healing
as well, even though the data are not conclusive. For instance, MMP-7 (matrilysin) has been
shown to be expressed in injured epithelia of various mucosal tissues, including lung, kidney,
cornea, and gut [58, 118–120], even though MMP-7 is not expressed in epidermal wounds. In
the lungs, MMP-7 has been demonstrated to play a role in inducing epithelial migration by
facilitating the shedding of syndecan-1, a transmembrane heparin sulfate proteoglycan [58].
In the same study, MMP-7 knockout mice displayed impaired re-epithelialization in the
mucosal tissue [58]. Also in the lungs, MMP-7 has been shown to cleave E-cadherin in the
process of facilitating cell migration away from the edge of the injured wound [118]. On the
other hand, another study has shown that MMP-7 and MMP-13 are expressed at the invasive
edge of tumors [121]. Another proteinase that might be important for the wound-repair process
is MMP-12 (metalloelastase), which is expressed by macrophages surrounding blood vessels
in acute murine excisional wounds [50]. Even though MMP-12 was not detected in either acute-
or chronic-wound tissues in the presence of macrophages, this proteinase expression was
found to be abundant in different human cutaneous granulomas [122]. In addition to its ability
to degrade fibrinogen interfering with blood clotting [123], MMP-12 is a potential regulator of
angiogenesis, since it was demonstrated to be most efficient at producing angiostatin [68].
Membrane-type MMPs might also be necessary for wound healing, more specifically MMP-14,
which is the most extensively studied to date (Table 1). The pivotal role of MMP-14 in
angiogenesis of wound healing may be attributed to the enzyme’s fibrinolytic and collageno-
lytic activity that is necessary for cell migration [71]. In addition, MMP-14 is needed for TIMP-2-
mediated activation of pro-MMP-2, a process that is coordinated by two MMP-14 molecules
and TIMP-2 [73]. Although MMP-14-deficient mice display abnormalities in bone develop-
ment, impaired angiogenesis, and defective type I collagen [93, 124], wound closure in these
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animals remains surprisingly unaffected (Table 3) [92]. However, MMP-14 has been demon-
strated to regulate cell proliferation by altering the expression of the KGF receptor during
wound healing in acute airway injury [72]. The overlapping functions of other membrane-type
MMPs or other MMPs may compensate for the absence of MMP-14 in these animals, support-
ing the concept of proteinase redundancy among MMPs.
2.2. Roles of MMPs in the pathology of chronic wounds
Cutaneous injuries that are recalcitrant to healing will become chronic wounds. In addition to
delayed wound closure, chronic wounds are characterized by excessive proteolysis, prolonged
inflammation, and failure in re-epithelialization [125]. Although MMPs play important roles
in restructuring the ECM and repairing the wounds, high levels of MMPs can be blamed for
increased proteolysis that leads to excessive degradation of ECM constituents and disruptions
of cell migration. These unwarranted events cause the wounds to enter a prolonged inflam-
mation. ELISA was used to document 65-fold higher levels of MMP-1, twofold higher of
MMP-8, and twofold lower of TIMP-2, whereas gelatin zymography showed 14-fold higher
levels of MMP-9, and sixfold higher of MMP-2 in diabetic foot ulcers than in non-diabetic
patients with acute wounds [49]. Up-regulation of MMPs hinders wound repair by degrading
ECM components and growth factors excessively [126]. As the wounds stay open too long, the
invading bacteria might also release bacterial proteinases to cause rapid degradation of growth
factors [94]. In order to defend the wounds against the invading microbes, the body will secrete
more ROS and inflammatory factors. High levels of ROS such as hydrogen peroxide cause
tissue damage [22], and high levels of inflammatory factors can lead to elevated expression of
MMPs, as discussed earlier. The delaying mechanism of this vicious cycle keeps the patient’s
wound in a chronic stage [127]. Most studies emphasize MMP-9 up-regulation, which is
associated with poor wound healing in diabetic foot ulcers and chronic wounds (Figure 6).
When high levels of exogenous MMP-9, parallel to human chronic wounds, was applied to
non-diabetic mice, this treatment delayed wound healing of the animals [128]. In one study,
up-regulated levels of MMP-9 were found in wound fluid from patients with unhealed diabetic
foot ulcers when compared with healed ulcers, as determined by gelatin zymography [129].
Also, in this same study, the researchers found decreased levels of TGF-β1 and TIMP-1 using
ELISA [129]. In another study of patients with diabetic foot ulcer, levels of MMP-9 were
measured by Western blot with MMP-9 antibody and were higher in patients with high risk
of developing foot ulcers [130]. Expression of this proteinase was detected in migrating
epithelial cells by ELISA [50, 51] and in inflammatory cells including T cells and neutrophils
by gelatin zymography [131, 132]. Nevertheless, it should be noted that increased levels of
MMPs, specifically that of MMP-9, as determined by ELISA, Western blot or gelatin zymog-
raphy do not necessarily imply that it is active or has any role in the pathology of chronic
wounds. ELISA and Western blot depend on the specificity of the antibodies, which likely
immunoreact with pro-MMPs, active MMPs, and TIMP-complexed MMPs. Similarly, the
active MMP-2 and MMP-9 bands detected by gelatin zymography could be from the TIMP-
complexed gelatinases that dissociate during electrophoresis [133]. Therefore, the expression
of MMP-9 found in many studies cannot be established conclusively as active MMP-9, the only
form of the proteinase that can modify substrates catalytically. Another common research
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method is the use of MMP knockout animals, which may provide further insights into the roles
of MMPs in wound healing (Table 3). However, the drawback of knockout animals is the
possibility of mechanistic compensation by other MMPs in the absence of the ablated MMP,
as discussed earlier. For instance, it has been shown that levels of MMP-9 are increased when
MMP-2 or MMP-8 are ablated [62, 134]. Also, many MMPs share the same substrates, indicat-
ing the redundancy in the proteinase functions of MMPs [3].
We described earlier the MMP-inhibitor-tethered affinity resin that Gooyit et al. used to identify
and accurately measure the levels of active MMP-9, which was found to be up-regulated in
diabetic mice with delayed wound healing [60]. The dual roles of MMPs are exhibited in this
case of MMP-9 up-regulation, which was demonstrated to be detrimental to diabetic wound
repair by topical treatment with two distinct selective MMP-9 inhibitors (ND-322 and
ND-336) [60, 63]. Inhibition of MMP-9 accelerated wound healing and promoted re-epitheli-
alization. It has been shown that MMP-9 inhibits cell replication during epithelial migration;
thus, MMP-9-deficient mice, both diabetic and non-diabetic, display a better rate of wound
closure [63, 64]. Similar to MMP-2, MMP-9 can also activate pro-TGF-β and release it from
LTBP [108, 109], while TGF-β has been shown to induce pro-MMP-9 in human skin [135]. Since
TGF-β1 is a cytokine that elicits recruitment of inflammatory cells during wound healing [136],
its up-regulation can regulate wound repair [137]. Interestingly, prolonged elevation in levels
of inflammatory cytokines, such as TGF-β, can lead to a prolonged inflammation phase and
consequentially delayed wound closure in diabetic mice [138]. However, it has also been shown
that non-diabetic MMP-9 knockout mice had delayed wound closure [70]. The apparent
conflicting role of MMP-9 may be explained by compensation of other MMPs, such as increased
expression of MMP-3 and MMP-13 in MMP-9 knockout animals [139]. In addition, the
redundancy of MMP substrates allow other MMP(s) to fulfill the same role, for instance
MMP-1, MMP-2, MMP-9, and MMP-13 have a role in keratinocyte migration and can replace
MMP-9 during normal wound healing [38, 70, 113, 140]. To date, topical application with a
selective MMP-9 inhibitor, by itself or in combination with recombinant MMP-8, has shown
therapeutic potential in accelerating murine diabetic wound healing [63]. These treatments
improve diabetic wound healing by increasing angiogenesis and restoring levels of inflam-
matory cytokines, including TGF-β1 [63].
3. Conclusions
MMPs exist in three forms―pro-MMPs, active MMPs, and TIMP-complexed MMPs―of which
only the active MMPs play a role in the pathology or repair of acute and chronic wounds.
Current methodologies do not distinguish between the three forms of MMPs. Thus, the roles
of MMPs in acute and chronic wounds are still not Qualitative and well-characterized
quantitative profiling of only the active form of MMPs is necessary for investigating the critical
roles of MMPs in remodeling the ECM during wound repair. We used a novel MMP-inhibitor-
tethered affinity resin that binds only the active form of MMPs, from which we identified and
quantified active MMP-8 and active MMP-9 in a murine diabetic model with delayed wound
healing [60]. We showed that up-regulation of active MMP-9 plays a detrimental role whereas
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active MMP-8 is involved in repairing the wound in diabetic mice [60, 63]. These studies
identified MMP-9 as a novel target for therapeutic intervention in the treatment of chronic
wounds. A selective inhibitor of MMP-9 that leaves MMP-8 unaffected would provide the most
effective therapy and represents a promising strategy for therapeutic intervention in the
treatment of diabetic foot ulcers.
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